Prevalence of Psychiatric Symptoms and Correlation Between Psychiatric Domain of ASI and Brief Psychiatric Rating Scale Among Patients with Substance Use Disorders in Northeastern Nigeria
Advances in Psychology and Neuroscience
Volume 2, Issue 2-1, March 2017, Pages: 21-26
Received: Sep. 25, 2016; Accepted: Sep. 30, 2016; Published: Feb. 14, 2017
Views 58      Downloads 1
Authors
Yerima Mukhtar Mohammed, College of Medical Sciences, Gombe State University, Gombe, Nigeria; Department of Medicine, Federal Teaching Hospital, Gombe, Nigeria
Onifade Peter Olutunde, Neuropsychiatric Hospital, Aro, Abeokuta, Nigeria
Ibrahim Abdu Wakawa, Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria; Federal Neuro-psychiatric Hospital, Maiduguri, Nigeria
Pindar Sadique Kwajaffa, Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria; Federal Neuro-psychiatric Hospital, Maiduguri, Nigeria
Jidda Mohammed Said, Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria; Federal Neuro-psychiatric Hospital, Maiduguri, Nigeria
Musami Umar Baba, Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria; Federal Neuro-psychiatric Hospital, Maiduguri, Nigeria
Wakil Musa Abba, Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria; Federal Neuro-psychiatric Hospital, Maiduguri, Nigeria
Article Tools
Follow on us
Abstract
The use of psychoactive substances is a common and ubiquitous behavior globally with considerable burden, mortality and morbidity. There is considerable degree of psycho-social, psychiatric and medical problems associated with the abuse of psychoactive substances. Few studies have examined the prevalence of psychiatric symptoms among patients with substance use disorders. Aims and Objectives: This study examined the prevalence of psychiatric symptoms and the concurrence of the Addiction Severity Index (ASI) psychiatric domain with Brief Psychiatric Rating Scale (BPRS). Methodology: a sample of 142 participants was selected purposively and administered the ASI and the BPRS after informed consent procedures. Results: The mean age of participants was 31 years (SD =8) and males were predominant (96.5%). The two most commonly used substances were Opioids (other than heroine) and Cannabis in 60.6% and 55.6% respectively. Twenty six (18.3%) patients reported depressive symptoms. Anxiety symptoms, Poor concentration, and suicidal thoughts were reported, respectively, by 30(21.1%), 17(12.0%), and 15(10.6%) patients. There was a strong positive correlation (r=0.862, p< .001) between the ASI psychiatric domain and the BPRS. Conclusion: participants had some symptoms of psychiatric disorders and there was a strong positive correlation between the ASI psychiatric domain and the BPRS.
Keywords
Prevalence, Psychiatric Symptoms, Substance Use Disorders, Concurrence ASI, BPRS
To cite this article
Yerima Mukhtar Mohammed, Onifade Peter Olutunde, Ibrahim Abdu Wakawa, Pindar Sadique Kwajaffa, Jidda Mohammed Said, Musami Umar Baba, Wakil Musa Abba, Prevalence of Psychiatric Symptoms and Correlation Between Psychiatric Domain of ASI and Brief Psychiatric Rating Scale Among Patients with Substance Use Disorders in Northeastern Nigeria, Advances in Psychology and Neuroscience. Special Issue:Substance Abuse: Perspectives, Trends, Issues and the Way Forward. Vol. 2, No. 2-1, 2017, pp. 21-26. doi: 10.11648/j.apn.s.2017020201.14
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet. 2012; 379(9810): 55-70.
[2]
Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. The Lancet. 2009; 373(9682): 2223-33.
[3]
Vega WA, Aguilar-Gaxiola S, Andrade L, Bijl R, Borges G, Caraveo-Anduaga JJ, et al. Prevalence and age of onset for drug use in seven international sites: results from the international consortium of psychiatric epidemiology. Drug and alcohol dependence. 2002; 68(3): 285-97.
[4]
Gureje O, Degenhardt L, Olley B, Uwakwe R, Udofia O, Wakil A, et al. A descriptive epidemiology of substance use and substance use disorders in Nigeria during the early 21st century. Drug and alcohol dependence. 2007; 91(1): 1-9.
[5]
Soyka M. Substance misuse, psychiatric disorder and violent and disturbed behaviour. The British Journal of Psychiatry. 2000; 176(4): 345-50.
[6]
Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. The British Journal of Psychiatry. 2008; 193(5): 357-63.
[7]
Perkins H. Surveying the damage: A review of research on consequences of alcohol misuse in college populations. Journal of Studies on Alcohol and Drugs. 2002(14):91.
[8]
Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. Bmj. 2002; 325(7374): 1195-8.
[9]
Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. The Lancet. 2004; 363(9421): 1579-88.
[10]
Schempf AH. Illicit drug use and neonatal outcomes: a critical review. Obstetrical & gynecological survey. 2007; 62(11): 749-57.
[11]
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet. 2007; 370(9584): 319-28.
[12]
Cleary M, Hunt GE, Matheson S, Walter G. Psychosocial treatments for people with co‐occurring severe mental illness and substance misuse: systematic review. Journal of Advanced Nursing. 2009; 65(2): 238-58.
[13]
Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment. JAMA: the journal of the American Medical Association. 2001; 286(14): 1715-23.
[14]
McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brlen CP. The effects of psychosocial services in substance abuse treatment. Journal of Addictions Nursing. 1993; 5(2): 38-47.
[15]
Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of substance abuse treatment. 2008; 34(1): 123-38.
[16]
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. Jama. 1990; 264(19): 2511-8.
[17]
Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. Psychiatric Services. 1989; 40(10): 1041-6.
[18]
Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Archives of General Psychiatry. 1988; 45(11): 1023-31.
[19]
Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophrenia bulletin. 2005; 31(3): 608-12.
[20]
Andréasson S, Engström A, Allebeck P, Rydberg U. Cannabis and schizophrenia A longitudinal study of swedish conscripts. The Lancet. 1987; 330(8574): 1483-6.
[21]
Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Bmj. 2002; 325(7374): 1212-3.
[22]
Krebs M-O, Goldberger C, Dervaux A. Cannabis use and schizophrenia. American Journal of Psychiatry. 2005; 162(2): 401-a-2.
[23]
Conner KR, Pinquart M, Gamble SA. Meta-analysis of depression and substance use among individuals with alcohol use disorders. Journal of substance abuse treatment. 2009; 37(2): 127-37.
[24]
Rodgers B, Korten A, Jorm AF, Jacomb P, Christensen H, Henderson AS. Non-linear relationships in associations of depression and anxiety with alcohol use. Psychological medicine. 2000; 30(02): 421-32.
[25]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. The British Journal of Psychiatry. 2005; 187(4): 366-71.
[26]
McLellan AT, Luborsky L, Woody GE, O'Brien CP, Kron R. Are the" Addiction-related" Problems of Substance Abusers Really Related? The Journal of nervous and mental disease. 1981; 169(4): 232-9.
[27]
Nock MK, Borges G, Bromet EJ, Alonso J, Angermeyer M, Beautrais A, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. The British Journal of Psychiatry. 2008; 192(2): 98-105.
[28]
Hall RC, Platt DE, Hall RC. Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts: evaluation of suicide risk in a time of managed care. Psychosomatics. 1999; 40(1): 18-27.
[29]
Gut-Fayand A, Dervaux A, Olié J-P, Lôo H, Poirier M-F, Krebs M-O. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry research. 2001; 102(1): 65-72.
[30]
Beck AT, Steer RA, Trexler LD. Alcohol abuse and eventual suicide: a 5-to 10-year prospective study of alcohol-abusing suicide attempters. Journal of Studies on Alcohol. 1989; 50(3): 202-9.
[31]
Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of general psychiatry. 2006; 63(7): 757-66.
[32]
Calsyn DA, Saxon AJ, Bush KR, Howell DN, Baer JS, Sloan KL, et al. The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug and Alcohol Dependence. 2004; 76(2): 165-71.
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-688-8931